Urolithiasis as an extra-articular manifestation of ankylosing spondilitis (literature review)


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article presents literature data on the incidence and risk factors for the development of urolithiasis in ankylosing spondylitis (ankylosing spondylitis), the features of the course of kidney damage and the underlying disease when they combined. The issues of the relationship between inflammation, calcium metabolism, kidney stone formation and osteoporosis (op) are discussed separately. The directions of further research to predict the development and prevention of kidney stone formation and the development of op in patients with ankylosing spondylitis have been determined. This review expands the doctors' understanding of comorbidity in inflammatory diseases of the joints and spine, in particular in ankylosing spondylitis.

Texto integral

Acesso é fechado

Sobre autores

Natalya Nikitina

Saratov State Medical University named after V.I. Razumovsky

Email: nikina02@yandex.ru
Dr. Sci. (Med.), Professor at the Department of Hospital Therapy, Faculty of General Medicine

Viktor Kharlamov

Saratov State Medical University named after V.I. Razumovsky

Email: viktor-stone@yandex.ru
Resident at the Department of Hospital Therapy, Faculty of General Medicine

Bibliografia

  1. Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г. и др. О терминологии спон-дилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 Doi: 10.14412/ 1995-4484-2015-657-660.
  2. Федеральные клинические рекомендации по диагностике и лечению анкилозирующего спондилита (болезнь Бехтерева). Общероссийская общественная организация «Ассоциация ревматологов России» Группа экспертов-разработчиков Бочкова А.Г., Дубинина Т. В., Закиров Р.Х. и др. [электронный ресурс www.rheumatolog.ru в рубрике Экспертный совет МЗ России]. 2013. 21 с.
  3. Vilar M.J., Cury S.E., Ferraz M.B., Sesso R., Atra E. Renal abnormalities in ankylosing spondylitis. Scand. J. Rheumatol. 1997;26(1):19-23. doi: 10.3109/03009749709065659.
  4. El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur. J. Intern. Med. 2011;22(6):554-60. doi: 10.1016/j.ejim.2011.06.006.
  5. Пленкина Л.В., Симонова О.В., Розинова В.А. Распространенность хронической болезни почек у пациентов с анкилозирующим спондилитом в Кировской области. Вятский медицинский вестник. 2019;4(64):8- 12 doi: 10.24411/2220-7880-2019-10026.
  6. Couderc M., Pereira B., Molto A., et al. The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study. J. Rheumatol. 2018; 45(6):795-801. Doi: 10.3899/ jrheum.170133.
  7. Моминова г.Н., Кулымбетова Б.А., Султанбекова А.О. и др. Опыт применения генно-инженерных препаратов у пациента с анкилозирующим спондилоартритом, осложненным АА-амилоидозом почек. Вестн. Казахского национального медицинского университета. 2018;2:501-
  8. Jakobsen A.K., Jacobsson L.T., Patschan O., et al. Surgical interventions for nephrolithiasis in ankylosing spondylitis and the general population. Scand. J. Urol. 2015; 21:1-6 Doi: 10.3109 / 21681805.2015.1089523.
  9. Korkmaz C., Ozcan A., Akзar N. Increased frequency of ultrasonographic findings suggestive of renal stones in patients with ankylosing spondylitis. Clin. Exp. Rheumatol. 2005; 23:389-92.
  10. Incel N.A., Gokoglu F., Nacir B., Incel N. Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis. Clin. Rheumatol. 2006; 25(5): 667-70. doi: 10.1007/s10067-005-0114-0.
  11. Canales B.K., Leonard S.M., Singh J.A., et al. Spondyloarthropathy: an independent risk factor for kidney stones. J. Endourol. 2006; 20(8):542-46. doi: 10.1089/end.2006.20.542.
  12. Cansu D.U., Cali§ir C., Sava§ Yava§ U., et al. Predictors of radiographic severity and functional disability in Turkish patients with ankylosing spondylitis. Clin. Rheumatol. 2011;30(4):557-62. doi: 10.1007/s10067-010-1665-2.
  13. Lui N.L., Carty A., Haroon N., et al. Clinical correlates of urolithiasis in ankylosing spondylitis. J. Rheumatol. 2011;38(9):1953-56. Doi: 10.3899/ jrheum.101175.
  14. Fallahi S., Jamshidi A.R., Gharibdoost F., et al. Urolithiasis in ankylosing spondylitis: Correlation with Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI) and Bath ankylosing spondylitis metrology index (BASMI). Caspian J. Intern. Med. 2012;3(4):508-13.
  15. Resorlu M., Gokmen F., Resorlu H., et al. Prospective evaluation of the renal morphology and vascular resistance in patients with ankylosing spondylitis. Med. Ultrason. 2015;17:180-84. doi: 10.11152/mu.2013.2066.172.dyr.
  16. Shih M.T., Tang S.H., Cha T.L., et al. The Risk of Nephrolithiasis Among Patients With Ankylosing Spondylitis: a Population-Based Cohort Study. Arch. Rheumatol. 2016;31(4):346-52. doi: 10.5606/ArchRheumatol.2016.5938.
  17. Sommerfleck F., Schneeberger E., Citera G. Comorbidities in Argentine patients with axial spondyloarthritis: Is nephrolithiasis associated with this disease? Eur. J. Rheumatol. 2018;5(3):169-72. doi: 10.5152/eurjrheum.2018.18002.
  18. Пленкина Л.В., Симонова О.В. Распространенность хронической болезни почек у пациентов с анкилозирующим спондилитом. Научнопрактическая ревматология. 2019;3.
  19. Korkmaz C., Sayer J.A. ANKH and renal stone formation in ankylosing spondylitis. J. Rheumatol. 2012;39(8):1756; author reply 1757. Doi: 10.3899/ jrheum.120161.
  20. Korkmaz C., Cansu D.U., Sayer J.A. Urolithiasis as an extraarticular manifestation of ankylosing spondylitis. Rheumatol Int. 2017;37(12):1949-56. doi: 10.1007/s00296-017-3788-0.
  21. Ben-Ami H., Ginesin Y., Behar D.M., et al. Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years. Can. J. Gastroenterol. 2002;16(4):225-29. doi: 10.1155/2002/204614.
  22. Sato S., Sasaki I., Naito H., et al. Management of urinary complications in Crohn's disease. Surg. Today. 1999;29(8):713-7. doi: 10.1007/BF02482314.
  23. Boussorra H., Sallami S., Said Y., et al. Evaluation of urolithiasis in Crohn’s disease in Tunisian patients. Tunis Med. 2013 ;91(7):440-43.
  24. Keddis M.T., Rule A.D. Nephrolithiasis and loss of kidney function. Curr. Opin. Nephrol. Hypertens. 2013;22(4):390-96. Doi:10.1097/ MNH.0b013e32836214b9.
  25. Vupputuri S., Soucie J.M., McClellan W., Sandler D.P. History of kidney stones as a possible risk factor for chronic kidney disease. Ann. Epidemiol. 2004;14(3):222-28. doi: 10.1016/S1047-2797(03)00126-1.
  26. Goyal N.K., Patil S., Goel A. Re: Long-term outcomes of percutaneous nephrolithotomy in 177patients with chronic kidney disease: a single center experience: Akman T., Binbay M., Aslan R., et al. J. Urol. 2012;187:173-7. J. Urol. 2012;188(1):333-34. doi: 10.1016/j.juro.2012.03.022.
  27. Moe O.W. Kidney stones: pathophysiology and medical management. Lancet. 2006;367(9507):333-44. doi: 10.1016/S0140-6736(06)68071-9.
  28. Gaspar S.R., Mendonga T., Oliveira P., et al. Urolithiasis and crohn's disease. Urol. Ann. 2016;8(3):297-304. doi: 10.4103/0974-7796.184879.
  29. GonUllU E., Bilge N.§.Y., Cansu D.U., et al. Risk factors for urolithiasis in patients with ankylosing spondylitis: a prospective case-control study. Urolithias. 2017;45(4):353-57. doi: 10.1007/s00240-016-0911-8.
  30. Oddsson A., Sulem P., Helgason H., et al. Common and rare variants associated with kidney stones and biochemical traits. Nat. Commun. 2015;6:7975. doi: 10.1038/ncomms8975.
  31. Curhan G.C., Willett W.C., Rimm E.B., Stampfer M.J. Family history and risk of kidney stones. J. Am. Soc. Nephrol. 1997;8(10):1568-73. Doi: https://doi.org/10.1681/ASN.V8101568.
  32. Stechman M.J., Loh N.Y., Thakker R.V. Genetics of hypercalciuric nephrolithiasis: renal stone disease. Ann. N. Y. Acad. Sci. 2007;1116:461-84. doi: 10.1196/annals.1402.030.
  33. Sayer J.A. The genetics of nephrolithiasis. Nephron. Exp. Nephrol. 2008;110(2):e37-43. doi: 10.1159/000151730.
  34. Chen B., Li J., He C., et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review). Mol. Med. Rep. 2017;15(4):1943-51. Doi: 10.3892/ mmr.2017.6248.
  35. Tsui F.W., Tsui H.W., Cheng E.Y., et al. Novel genetic markers in the 5'-flanking region of ANKH are associated with ankylosing spondylitis. Arthr. Rheum. 2003;48(3):791-97. doi: 10.1002/art.10844.
  36. Tsui H.W., Inman R.D., Paterson A.D., et al. ANKH variants associated with ankylosing spondylitis: gender differences. Arthr. Res. Ther. 2005;7(3):R513- 25. doi: 10.1186/ar1701.
  37. Liu Z., Cui Y., Zhou X., et al. Association of mineralization-related genes TNAP and ANKH polymorphisms with ankylosing spondylitis in the Chinese Han population. Biosci. Trends. 2013;7(2):89-92. Doi: 10.5582 / bst.2013.v7.2.89.
  38. Ho A.M., Johnson M.D., Kingsley D.M. Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 2000;289(5477):265-70. doi: 10.1126/science.289.5477.265.
  39. Russell R.G. Metabolism of inorganic pyrophosphate (PPi). Arthr. Rheum. 1976;19(Suppl. 3):465-78. doi: 10.1002/1529-0131(197605/ 06)19:3+<465::aid-art1780190722>3.0.co;2.
  40. Moochhala S.H., Sayer J.A., Carr G., Simmons N.L. Renal calcium stones: insights from the control of bone mineralization. Exp. Physiol. 2008;93(1): 43-9. doi: 10.1113/expphysiol.2007.040790.
  41. Carr G., Sayer J.A., Simmons N.L. Expression and localisation of the pyrophosphate transporter, ANK, in murine kidney cells. Cell. Physiol. Biochem. 2007;20(5):507-16. doi: 10.1159/000107534.
  42. Zhang L., Han R., Zhang X., et al. Fecal microbiota in patients with ankylosing spondylitis: Correlation with dietary factors and disease activity. Clin. Chim. Acta. 2019;497:189-96. doi: 10.1016/j.cca.2019.07.038.
  43. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Sci. 2006;314(5804):1461-63. doi: 10.1126/science.1135245.
  44. Rahman P., Inman R.D., Gladman D.D., et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthr. Rheum. 2008;58(4): 1020-25. doi: 10.1002/art.23389.
  45. van Sommeren S., Janse M., Karjalainen J., et al. Extraintestinalmanifestations and complications in inflammatory bowel disease: from shared genetics to shared biological pathways. Inflamm. Bowel Dis. 2014;20(6):987-94. doi: 10.1097/MIB.0000000000000032.
  46. Turin a M.C., Sieper J., Yeremenko N., et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann. Rheum. Dis. 2014;73(9):1746-48. Doi: 10.1136/ annrheumdis-2014-205506.
  47. Matzkies F.G., Targan S.R., Berel D., et al. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthr. Res. Ther. 2012;14(6):R261. doi: 10.1186/ar4106.
  48. Targan S.R., Landers C.J., Yang H., Antibodies to CBir1flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterol. 2005;128(7):2020-28. doi: 10.1053/j.gastro.2005.03.046.
  49. Veys E.M., van Leare M. Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann. Rheum. Dis. 1973;32(6):493-96. doi: 10.1136/ard.32.6.493.
  50. Shodjai-Moradi F., Ebringer A., Abuljadayel I. IgA antibody response to klebsiella in ankylosing spondylitis measured by immunoblotting. Ann. Rheum. Dis. 1992;51(2):233-37. doi: 10.1136/ard.51.2.233.
  51. Ardigoglu O., Atay M.B., Ataoglu H., et al. Ig A antibodies to klebsiella in ankylosing spondylitis. Clin. Rheumatol. 1996;15(6):573-76. Doi: 10.1007/ BF02238546.
  52. Klingberg E., Lorentzon M., Mellstrom D., et al. Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthr. Res. Ther. 2012;14(3):R108. doi: 10.1186/ar3833].
  53. Grubisic F., Grazio S., Balenovic A. Osteoporosis, spinal mobility and chest expansion index in patients with ankylosing spondylitis. Coll. Antropol. 2014;38(1):63-8.
  54. Munoz-Ortego J., Vestergaard P., Rubio J.B. Ankylosing spondylitis is associated with an increased risk of vertebral and non vertebral clinical fractures: a population-based cohort study. J. Bone Miner. Res. 2014;29(8):1770-76. doi: 10.1002/jbmr.2217.
  55. El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine. 2004;71(4):291-95. doi: 10.1016/j.jbspin.2003.06.002.
  56. Ou S.M., Chen Y.T., Shih C.J., Tarng D.C. Increased risk of bone fracture among patients with urinary calculi: a nationwide longitudinal population-based study. Osteoporos Int. 2015;26(4):1261-69. Doi: 10.1007/ s00198-014-2998-5.
  57. Klingberg E., Nurkkala M., Carlsten H., Forsblad-d'Elia H. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J. Rheumatol. 2014;41(7):1349-56. Doi: 10.3899/ jrheum.131199.
  58. Appel H., Ruiz-Heiland G., Listing J., et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthr. Rheum. 2009;60(11):3257-62. doi: 10.1002/art.24888.
  59. Saad C.G., Ribeiro A.C., Moraes J.C., et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthr. Res. Ther. 2012;14(5):R216. Doi: 10.1186/ ar4055.
  60. Gratacos J., Collado A., Filella X., et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. J. Rheumatol. 1994;33(10):927-31. doi: 10.1093/rheumatology/33.10.927.
  61. Gratacos J., Collado A., Pons F., et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a follow up study. Arthr. Rheum. 1999;42(11):2319-24. doi: 10.1002/1529-0131(199911)42: 11<2319:AID-ANR9>3.0.CO;2-G.
  62. Pacifici R. Idiopathic hypercalciuria and osteoporosis--distinct clinical manifestations of increased cytokine-induced bone resorption? J. Clin. Endocrinol. Metab. 1997;82(1):29-31. doi: 10.1210/jcem.82.1.3706.
  63. Will R., Palmer R., Bhalla A.K., Ring F., Calin A. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet. 1989; 2(8678-79):1483-85. doi: 10.1016/s0140-6736(89)92932-2.
  64. Яровой С.К., Максудов Р.Р. Нефролитиаз и метаболические остеопатии на фоне соматических заболеваний. ЭКУ. 2015; 1:2015.
  65. Hess B. Drug-induced urolithiasis. Curr. Opin Urol. 1998;8(4):331-34.
  66. Rezvani A., Aktas I., Tastekin N., et al. Nephrolithiasis in ankylosing spondylitis and its relationship with disease assessment scales. North Clin. Istanb. 2018;6(3):254-59. doi: 10.14744/nci.2018.58219.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar